Dianthus Therapeutics (NASDAQ:DNTH) Price Target Cut to $50.00 by Analysts at Robert W. Baird

Dianthus Therapeutics (NASDAQ:DNTH) had its target price reduced by Robert W. Baird from $58.00 to $50.00 in a research note released on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other equities analysts also recently weighed in on DNTH. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday. Finally, Guggenheim reaffirmed a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $53.00.

Dianthus Therapeutics Stock Down 6.2%

Shares of DNTH stock opened at $18.84 on Tuesday. Dianthus Therapeutics has a 12-month low of $13.37 and a 12-month high of $32.27. The company has a market capitalization of $605.25 million, a P/E ratio of -7.54 and a beta of 1.48. The firm has a 50-day moving average price of $19.68 and a 200 day moving average price of $22.30.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million. As a group, research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. American Century Companies Inc. grew its holdings in Dianthus Therapeutics by 8.7% during the first quarter. American Century Companies Inc. now owns 47,817 shares of the company’s stock valued at $867,000 after purchasing an additional 3,821 shares during the period. Nuveen LLC bought a new stake in shares of Dianthus Therapeutics in the first quarter worth $1,168,000. Invesco Ltd. lifted its position in shares of Dianthus Therapeutics by 38.7% in the first quarter. Invesco Ltd. now owns 15,978 shares of the company’s stock worth $290,000 after purchasing an additional 4,457 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company’s stock worth $3,049,000 after purchasing an additional 1,081 shares in the last quarter. Finally, US Bancorp DE raised its position in Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after acquiring an additional 1,510 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.